Grifols, S.A. (GRFS): Price and Financial Metrics

Grifols, S.A. (GRFS): $9.37

0.28 (-2.90%)

POWR Rating

Component Grades








Add GRFS to Watchlist
Sign Up

GRFS Price/Volume Stats

Current price $9.37 52-week high $10.97
Prev. close $9.65 52-week low $5.71
Day low $9.35 Volume 281,000
Day high $9.60 Avg. volume 821,665
50-day MA $9.92 Dividend yield N/A
200-day MA $8.81 Market Cap 6.44B

GRFS Stock Price Chart Interactive Chart >


  • Value is the dimension where GRFS ranks best; there it ranks ahead of 86.12% of US stocks.
  • GRFS's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • GRFS ranks lowest in Momentum; there it ranks in the 9th percentile.

GRFS Stock Summary

  • For GRFS, its debt to operating expenses ratio is greater than that reported by 87.12% of US equities we're observing.
  • With a year-over-year growth in debt of 61.16%, GRIFOLS SA's debt growth rate surpasses 86.26% of about US stocks.
  • As for revenue growth, note that GRFS's revenue has grown 29.28% over the past 12 months; that beats the revenue growth of 80.75% of US companies in our set.
  • Stocks that are quantitatively similar to GRFS, based on their financial statements, market capitalization, and price volatility, are OSPN, ATRC, ZUMZ, MDXG, and BLFY.
  • Visit GRFS's SEC page to see the company's official filings. To visit the company's web site, go to

Grifols, S.A. (GRFS) Company Bio

Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories. (Source:Wikipedia)

GRFS Latest News Stream

Event/Time News Detail
Loading, please wait...

GRFS Latest Social Stream

Loading social stream, please wait...

View Full GRFS Social Stream

Latest GRFS News From Around the Web

Below are the latest news stories about GRIFOLS SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.

GRFS or STVN: Which Is the Better Value Stock Right Now?

GRFS vs. STVN: Which Stock Is the Better Value Option?

Yahoo | September 14, 2023

Grifols (GRFS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | September 12, 2023

Should Value Investors Buy Grifols (GRFS) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Yahoo | September 12, 2023

Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics

Grifols will apply artificial intelligence technologies, including large language models, to speed up the development of new biopharma therapeuticsAgreement is latest Grifols initiative to reinforce the robustness of its therapeutic pipeline and strengthen its innovation culture BARCELONA, Spain, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people’s health and

Yahoo | August 1, 2023

Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every two weeks, compared with weekly, in patients with primary immunodeficienciesStudy designed to support extending U.S. Food and Drug Administration labeling of XEMBIFY® to include biweekly dosing, providing added flexibility and convenience for patientsGrifols is accelerating adoption of XEMBIFY® as part of its broader immunoglobulin business st

Yahoo | July 20, 2023

Read More 'GRFS' Stories Here

GRFS Price Returns

1-mo -5.73%
3-mo 4.93%
6-mo 36.79%
1-year 21.06%
3-year -38.58%
5-year -53.25%
YTD 10.24%
2022 -24.31%
2021 -37.78%
2020 -20.15%
2019 28.71%
2018 -18.50%

Continue Researching GRFS

Here are a few links from around the web to help you further your research on Grifols SA's stock as an investment opportunity:

Grifols SA (GRFS) Stock Price | Nasdaq
Grifols SA (GRFS) Stock Quote, History and News - Yahoo Finance
Grifols SA (GRFS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!